- Home
- IDN vs NTHI Comparison
IDN vs NTHI Comparison
Compare IDN & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IDN
- NTHI
- Stock Information
- Founded
- IDN 1994
- NTHI 2008
- Country
- IDN United States
- NTHI United States
- Employees
- IDN N/A
- NTHI N/A
- Industry
- IDN Computer Software: Prepackaged Software
- NTHI Biotechnology: Pharmaceutical Preparations
- Sector
- IDN Technology
- NTHI Health Care
- Exchange
- IDN Nasdaq
- NTHI Nasdaq
- Market Cap
- IDN 120.5M
- NTHI 142.5M
- IPO Year
- IDN 1999
- NTHI N/A
- Fundamental
- Price
- IDN $5.35
- NTHI $3.75
- Analyst Decision
- IDN Strong Buy
- NTHI
- Analyst Count
- IDN 3
- NTHI 0
- Target Price
- IDN $5.83
- NTHI N/A
- AVG Volume (30 Days)
- IDN 481.3K
- NTHI 24.1K
- Earning Date
- IDN 08-07-2025
- NTHI 01-01-0001
- Dividend Yield
- IDN N/A
- NTHI N/A
- EPS Growth
- IDN N/A
- NTHI N/A
- EPS
- IDN N/A
- NTHI N/A
- Revenue
- IDN $20,211,000.00
- NTHI $79,990.00
- Revenue This Year
- IDN $9.35
- NTHI N/A
- Revenue Next Year
- IDN $13.05
- NTHI N/A
- P/E Ratio
- IDN N/A
- NTHI N/A
- Revenue Growth
- IDN 4.55
- NTHI 13.52
- 52 Week Low
- IDN $1.92
- NTHI $3.50
- 52 Week High
- IDN $6.49
- NTHI $25.00
- Technical
- Relative Strength Index (RSI)
- IDN 59.07
- NTHI N/A
- Support Level
- IDN $5.21
- NTHI N/A
- Resistance Level
- IDN $5.97
- NTHI N/A
- Average True Range (ATR)
- IDN 0.39
- NTHI 0.00
- MACD
- IDN -0.10
- NTHI 0.00
- Stochastic Oscillator
- IDN 29.01
- NTHI 0.00
About IDN Intellicheck Inc.
Intellicheck Inc is a trusted industry leader in technology solutions that stop identity theft and fraud with real-time identification authentication and age verification. The group delivers on-demand digital and physical identity verification solutions for KYC, AML, fraud prevention, and age verification needs. The products of the company include solutions for preventing identity fraud across any industry delivered via smartphone, tablet, POS integration or other electronic devices.
About NTHI NeOnc Technologies Holdings Inc. Common Stock
NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration ("FDA").